TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00166517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: 3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: 3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
Study: NCT00065442

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sipuleucel-T
Description: Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: APC-Placebo
Description: Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
Study: NCT04451317

Intervention type: OTHER
Intervention: Questionnaire, phone call
Description: phone call and 3 questionnaires on a digital platform

Intervention type: OTHER
Intervention: Questionnaire, phone call
Description: phone call and 3 questionnaires on a digital platform
Study: NCT00934011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C-reactive protein guided antibiotic therapy
Description: plasma CRP measurement to guide the duration of antibiotic therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procalcitonin guided antibiotic therapy
Description: plasma PCT measurement to guide the duration of antibiotic therapy
Study: NCT02924818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Study: NCT02038907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
Study: NCT03623698

Intervention type: DRUG
Intervention: Nebulised hypertonic saline
Description: Nebulised hypertonic saline used for a period of at least 12 months
Study: NCT02924818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Study: NCT03432494

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcaval closure device (TCD)
Description: Transcaval access and closure using the Transmural Transcaval Closure Device (TCD) at the time of medically-necessary transcatheter aortic valve replacement (TAVR).
Study: NCT05412264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website intervention
Description: 12 week motivational emails, recording pedometer steps and waist circumference
Study: NCT02924818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study: NCT02654496

Intervention type: OTHER
Intervention: Meal challenge
Description: Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
Study: NCT02924818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires
Study: NCT02654496

Intervention type: OTHER
Intervention: Meal challenge
Description: Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.

Intervention type: OTHER
Intervention: Meal challenge
Description: Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
Study: NCT00644943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: oral suspension (7 mg/kg, ql2hr) for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: oral suspension (45 mg/kg/day, q l2 hours) for 10 days
Study: NCT00531596

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 9mg/24Hr
Description: EMSAM 9mg/24Hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMSAM (Selegiline Transdermal System) 12mg/24hr
Description: EMSAM 12mg/24Hr
Study: NCT00912574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF-in-adjuvant
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA-51
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study: NCT02924818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionnaires

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary function test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary function test
Study: NCT00912574

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF and Montanide ISA-51
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1. 1 ml saline~2. specified dose of GM-CSF in 1 ml saline~3. an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~4. an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant
Study: NCT04202185

Intervention type: OTHER
Intervention: Data collection
Description: Retrospective collection data from diagnostic Data collected following to medical exam as part of care

Intervention type: OTHER
Intervention: Data collection
Description: Retrospective collection data from diagnostic Data collected following to medical exam as part of care
Study: NCT01309932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Lambda (pegIFNλ)
Description: Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
Study: NCT02924818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary function test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary function test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pulmonary function test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood test

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbiology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbiology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbiology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbiology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbiology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histology

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: histology

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging
Study: NCT02038907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
Study: NCT02924818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: imaging
Study: NCT02038907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus Bivalent VLP Vaccine
Description: Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
Study: NCT02608138

Intervention type: OTHER
Intervention: Iodine status among portuguese school children
Study: NCT02846805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant-retained overdentures
Description: subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
Study: NCT01265342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Description: Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nebulised suspension twice a day for 10 days
Study: NCT02628951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
Study: NCT02889757

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acteylcysteine
Description: randomized into three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acteylcysteine
Description: randomized into three arms
Study: NCT00872482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nimotuzumab
Description: Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
Study: NCT02158286

Intervention type: OTHER
Intervention: Measuring emptying rate from the gastric tube
Study: NCT03172663

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pure tone audiometry
Description: for estimate the type and degree of hearing loss
Study: NCT02889757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acteylcysteine
Description: randomized into three arms
Study: NCT01875510

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish-oil emulsions
Description: Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish-oil emulsions
Description: Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soybean-oil emulsion
Description: soybean-oil emulsion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: soybean-oil emulsion
Description: soybean-oil emulsion
Study: NCT00659126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3 Tesla Magnetic Resonance Imaging
Description: Undergo 3T MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Field Strength Magnetic Resonance Imaging
Description: Undergo 7T MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Susceptibility Weighted Imaging
Description: Undergo SWI
Study: NCT03172663

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pure tone audiometry
Description: for estimate the type and degree of hearing loss
Study: NCT04281017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA
Description: Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced anesthesia
Description: Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg
Study: NCT03381209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: sugammadex given based on 3 measurements of body weights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: sugammadex given based on 3 measurements of body weights

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: sugammadex given based on 3 measurements of body weights
Study: NCT04202185

Intervention type: OTHER
Intervention: Data collection
Description: Retrospective collection data from diagnostic Data collected following to medical exam as part of care

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Research of mutation and identification of genetic panel as part of care

Intervention type: GENETIC
Intervention: Genetic analysis
Description: Research of mutation and identification of genetic panel as part of care
Study: NCT03604497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: beacon alerts
Description: alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no alerts retention
Description: no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
Study: NCT01460810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1000CsK Silicon Oil Tamponade
Description: Details covered in arm description
Study: NCT01797757

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil enriched with EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil enriched with EPA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG-EPA oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MAG-EPA oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orlistat
Study: NCT01239771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two subjects in each cohort will be given placebo.
Study: NCT02982811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-ACT
Description: 3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
Study: NCT03830918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Given IV
Study: NCT03498547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: saddle block
Description: In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
Study: NCT02150213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI, CT or ultrasound was permitted if MRI was contraindicated
Description: MRI/CT/ultrasound of abdomen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dexamethasone Supression Test
Description: Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonogram
Description: Sonogram of the uterus (females only)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Uterine endometrial biopsy (females only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Description: No study-drug was administered in this study
Study: NCT03379896

Intervention type: OTHER
Intervention: Collect peripheral blood sample
Description: Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.

Intervention type: OTHER
Intervention: Collect peripheral blood sample
Description: Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
Study: NCT01125293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study: NCT04108819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.